James Yang, MD
Pulmonary Disease · Honolulu, HINPI 1427442904
Payments from drug & device makers
What this record shows
This record is dominated by education: $5,500 of the $8,463 with a category attached, or 65.0%. Intuitive Surgical accounts for 77.1% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2024 at $6,782 and has fallen 91.9% since, to $546 in 2025.
Across 52 payments — averaging $162.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- Amgen$505
- Insmed, Inc.$381
- Galvanize Therapeutics, Inc$251
- Novo Nordisk$169
- Inari Medical, Inc.$145
- plus $487 from 12 others
What the payments were for
- Travel & lodging$1,02512%
- Food & beverage$1,93823%
- Education$5,50065%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 6 | $6,525 |
| Amgen | 5 | $505 |
| Insmed, Inc. | 12 | $381 |
| Galvanize Therapeutics, Inc | 1 | $251 |
| Novo Nordisk | 8 | $169 |
| Inari Medical, Inc. | 1 | $145 |
| AstraZeneca | 2 | $127 |
| Boehringer Ingelheim | 3 | $67 |
| GSK | 3 | $48 |
| Amarin Pharma, Inc. | 2 | $44 |
| Ironwood Pharmaceuticals, Inc | 2 | $41 |
| Harmony Biosciences LLC | 1 | $38 |
| Nestle Healthcare Nutrition Inc. | 1 | $27 |
| Johnson & Johnson | 1 | $25 |
| Merck | 1 | $22 |
| Philips North America LLC | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Lilly USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$6,506
- Brinsupri$270
- ALIYA SYSTEM$251
- AIMOVIG$234
- FLOWTRIEVER CATHETER, S$145
- CT THROMBECTOMY SYSTEM KIT$145
- Arikayce$125
- Prolia$117
- BREZTRI$111
- Repatha$106
How this compares
$8,463 in reported general payments places this provider in the 70th percentile of 44 pulmonary disease providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ArikayceAmikacin Liposomal/Neb.Accessr | 11 | $165,199 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $26,392 |
| EliquisApixaban | 49 | $20,180 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 25 | $18,981 |
| Incruse ElliptaUmeclidinium Bromide | 32 | $14,016 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $10,560 |
| DapagliflozinDapagliflozin Propanediol | 18 | $5,738 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $5,494 |
| EntrestoSacubitril/Valsartan | 17 | $5,469 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,219 |
| JardianceEmpagliflozin | 13 | $3,675 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $2,729 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $1,937 |
| Wixela InhubFluticasone Propion/Salmeterol | 17 | $1,404 |
| Amiodarone Hcl | 11 | $1,315 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Insmed, Inc.Arikayce | $381 | $165,19911 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta | $48 | $45,62876 claims |
| Boehringer IngelheimStiolto Respimat, Jardiance | $67 | $22,65638 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $127 | $13,28826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 44 pulmonary disease providers in Hawaii.
Other pulmonary disease in Honolulu
- Takkin LoHonolulu$324K
- Bradley TokeshiHonolulu$41K
- Ernie YimHonolulu$20K
- Eric CrawleyHonolulu$17K
- Samuel EvansHonolulu$15K
- Ronson SatoHonolulu$14K
- Alvin FuruikeHonolulu$10K
- Katsufumi NishidaHonolulu$8K
- Sheri Shimizu-SaitoHonolulu$8K
- Jennifer KayaHonolulu$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.